The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. (2012)

First Author: IST-3 Collaborative Group
Attributed to:  Edinburgh Trials Methodology Hub funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(12)60768-5

PubMed Identifier: 22632908

Publication URI: http://europepmc.org/abstract/MED/22632908

Type: Journal Article/Review

Volume: 379

Parent Publication: Lancet (London, England)

Issue: 9834

ISSN: 0140-6736